Yanbo Wang, Zhen Du, Haowei Du, Jianchun Zhao, Yuting Duan, Aimin Wang
{"title":"Associations between dietary intake of zinc and selenium and breast cancer: findings from a NHANES cross-sectional study.","authors":"Yanbo Wang, Zhen Du, Haowei Du, Jianchun Zhao, Yuting Duan, Aimin Wang","doi":"10.21037/cco-24-83","DOIUrl":"10.21037/cco-24-83","url":null,"abstract":"<p><strong>Background: </strong>zinc and selenium are essential trace elements that have been suggested to influence cancer development, but their relationship with breast cancer remains unclear. Additionally, biomarkers such as bilirubin, uric acid, and gamma glutamyl transferase (GGT) are associated with various metabolic processes that could affect cancer progression. This research aimed to examine the associations between zinc and selenium levels and breast cancer, and the extent to which bilirubin, uric acid and GGT mediate the effect on breast cancer.</p><p><strong>Methods: </strong>In all, 25,244 females were enrolled from the 1999-2020 National Health and Nutrition Examination Survey (NHANES). The associations between zinc and selenium intake and prevalent breast cancer were explored through meticulous adjustments for covariates utilizing both multivariate and stratified logistic regression analyses. Furthermore, the mediation and interaction effects were performed by mediation analyses and generalized linear model.</p><p><strong>Results: </strong>Prevalent breast cancer was associated with race, marital status and age. Additionally, participants with breast cancer showed lower zinc (10.2 vs. 12.0 mg, P=0.001) and selenium levels (95.7 vs. 114.4 µg, P<0.001) and higher incidence of diabetes (2.60% vs. 97.40%, P<0.001) and cardiovascular disease (CVD) (3.07% vs. 96.93%, P<0.001) comorbidities than the control group. Logistic regression analysis showed a strong linear protective association between zinc and selenium levels and breast cancer. After further adjustment in Model 3, statistical significance remained for each unit increase in selenium [odds ratio (OR), 0.66; 95% confidence interval (CI): 0.47-0.93; P=0.02], as well as for Q4 versus Q1 for zinc (OR, 0.48; 95% CI: 0.27-0.86; P=0.01). In addition, a significant age-effect modification was observed for zinc (Pinteraction=0.07) associations were stronger in women aged over 40 years compared to younger women. Finally, bilirubin potentially mediated the protective association between zinc and breast cancer, while bilirubin, uric acid, and GGT levels mediated approximately 10% of the relationship between selenium and breast cancer.</p><p><strong>Conclusions: </strong>Our study highlighted negative correlations between zinc and selenium intake and breast cancer in women. The mediation analysis has shown that bilirubin, uric acid and GGT play an indirect role.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 1","pages":"2"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Is metastasis-directed local therapy the new standard of care for patients with oligometastasic esophageal squamous cell carcinoma?-a perspective on the ESO-Shanghai 13 Trial.","authors":"Neil B Newman, Krishan R Jethwa","doi":"10.21037/cco-24-57","DOIUrl":"10.21037/cco-24-57","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"13"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Intriguing future: single-site robotic-assisted radical prostatectomy.","authors":"Di Gu, Yubo Wang, Yifan Chang, Yongda Liu, Mingzhao Li, Chao Cai, Shancheng Ren, Guohua Zeng","doi":"10.21037/cco-24-96","DOIUrl":"10.21037/cco-24-96","url":null,"abstract":"<p><p>Single-site robotic-assisted radical prostatectomy (ssRARP) has emerged as a promising advancement in urological surgery, driven by the development of advanced robotic instrumentation and single-port access technologies. Global researchers have extensively explored various techniques and approaches for ssRARP in carefully selected patient populations, yielding promising perioperative and oncological outcomes. This review aims to provide a comprehensive overview of the technical intricacies of ssRARP. We will delve into the evolution of single-port robotic surgery, highlighting key advancements and surgical techniques, including transperitoneal, extraperitoneal, and transvesical approaches. A detailed discussion of technical nuances, challenges, and potential pitfalls will be presented. Furthermore, we will analyze the available evidence regarding the perioperative and oncological outcomes of ssRARP. This includes examining factors such as operative time, blood loss, postoperative complications, length of hospital stay, continence recovery, and biochemical recurrence-free survival, and the challenges and management strategies for patients with specific preoperative situations, such as previous surgery, large median lobe and prostatectomy after focal therapy. The potential advantages of ssRARP, including improved cosmesis, reduced postoperative pain, and faster recovery, will be explored. By providing a comprehensive understanding of the technical aspects, clinical outcomes, and future directions of ssRARP, this review aims to contribute to the ongoing discourse on the role of single-port robotic surgery in prostate cancer management.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"9"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bibliometrics of gastric cancer prediction models.","authors":"Fei Gao, Xiaohan Wang, Xifeng Fu, Jingchao Sun","doi":"10.21037/cco-24-63","DOIUrl":"10.21037/cco-24-63","url":null,"abstract":"<p><p>This paper analyzes the manuscripts in the field of gastric cancer (GC) prediction, guiding clinical work and prevention of GC. Using a search strategy, we retrieved research articles related to GC prognosis from the Web of Science (WOS) core database: topic search (TS) = ((gastric cancer OR stomach cancer) AND (survival rate OR survival analysis OR prognosis) AND (predict model)). We set the language to English, the document type to article and review, and completed the search on July 1, 2023. We obtained 1,598 relevant articles, and two researchers screened the search results again, excluding irrelevant, misclassified, and retracted articles. Any controversial articles were reviewed by a third researcher to make the final decision on the required literature. We finally selected 1,056 articles, excluding 542 articles, and extracted the required data from the WOS database for analysis. The extracted database included: title, publication year, author, country/region, institution, citation count, journal, keyword, and reference. We used R (4.3.0) to load the R package (bibliometrix) for bibliometric analysis. The 1,056 articles came from 273 sources (journals, books, etc.), and 3,661 authors conducted relevant research on GC prognosis models. Frontiers in Oncology published the most articles (N=72), and Gastric Cancer Journal had the most citations (N=1,130). The publication time span ranged from 1991 to 2023, with an average annual growth rate of 13.31%. The number of publications increased from 2017, with a sharp increase from 2020 to 2023. The five countries with the most publications were China (n=826), Japan (n=62), Korea (n=47), USA (n=42), Italy (n=19). China had the most citations (N=9,595), and USA had the highest average citation per article (44.9 times). The most common topic was GC survival (n=236), followed by expression (n=209). Multiple GC prediction models in this study describe the science of predicting GC incidence and prognosis. This work provides the most influential references related to GC prediction and serves as a guide for citable papers.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 1","pages":"6"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ying Chen, Hongyu Shen, Ruiqin Xu, Jiahai Zhu, Ya Zhu, Hao Zou
{"title":"Comparative prognosis of liver transplantation versus liver resection in intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.","authors":"Ying Chen, Hongyu Shen, Ruiqin Xu, Jiahai Zhu, Ya Zhu, Hao Zou","doi":"10.21037/cco-24-86","DOIUrl":"10.21037/cco-24-86","url":null,"abstract":"<p><strong>Background: </strong>Liver resection (LR) remains the only curative approach for patients diagnosed with intrahepatic cholangiocarcinoma (ICC). Although margin-negative resection can be achieved, long-term oncological outcomes still need improvement. Recent studies from both single and multi-institutional settings have indicated that liver transplantation (LT) could be a feasible treatment option for ICC under particular conditions. While some research has compared LT with LR in treating ICC patients, the results of these comparisons remain controversial. This meta-analysis compares the surgical outcomes of LT and LR for ICC.</p><p><strong>Methods: </strong>We conducted a thorough search of the Cochrane Library, Web of Science, and PubMed for articles comparing the ICC of LT and LR published from January 2000 to April 2024. The studies' relevance and quality were assessed independently by two investigators. Odds ratios (ORs) were utilized to evaluate dichotomous data, and fixed-effects were employed for meta-analyses.</p><p><strong>Results: </strong>Five studies were analyzed in this meta-analysis, revealing no significant difference in 1-year overall survival rates between LT and LR. However, LT showed significantly higher 3-year, and 5-year overall survival rates compared to LR, with ORs of 1.39 [95% confidence interval (CI): 1.04-1.84, P=0.02] at 3 years, 1.71 (95% CI: 1.30-2.26, P<0.001) at 5 years. The advantage of LT over LR in terms of overall survival became evident at 3 years, 5 years, and post-operation, despite not being apparent in the first year. Additionally, the R0 resection rate was higher following LT than LR (P=0.006), potentially contributing to the superior long-term outcomes of LT. Subgroup analysis revealed no statistically significant difference in survival outcomes between the two treatment regimens when LT failed to achieve R0 resection.</p><p><strong>Conclusions: </strong>For patients with ICC, LT seems to have optimistic survival results under certain conditions compared with curative hepatectomy. Since LT is a potential treatment for ICC, it is currently uncertain whether LT should be more considered in patients with ICC. Further prospective trials are required to demonstrate its efficacy in the future.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 1","pages":"3"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nosakhare Paul Ilerhunmwuwa, Ibrahim Halil Sahin, Anwaar Saeed
{"title":"Immunotherapy resistance in colorectal cancer with liver metastases: challenges & therapeutic advances.","authors":"Nosakhare Paul Ilerhunmwuwa, Ibrahim Halil Sahin, Anwaar Saeed","doi":"10.21037/cco-24-93","DOIUrl":"10.21037/cco-24-93","url":null,"abstract":"<p><p>Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide, with liver metastasis (LM) being the most common site of spread. The emergence of immunotherapy has changed the landscape of cancer treatment, providing therapeutic options for the management of CRC, especially in metastatic settings. Typically, CRC with microsatellite instability-high (MSI-H) status respond more favorably than those that are microsatellite stable (MSS). However, it has been observed that the presence of LMs limits the efficacy of immunotherapy irrespective of the microsatellite instability (MSI) status, which presents unique challenges in managing CRC with LMs (CRCLM). The exact mechanisms for resistance to immunotherapy in CRCLM are poorly understood. Several factors in the liver tumor microenvironment (TME) have been linked to therapeutic failures with immunotherapy in CRCLM. Novel agents that explore and target immunosuppressive elements in the liver TME, such as the lymphocyte activation gene 3 (LAG-3) and vascular endothelial growth factor receptor (VEGFR), in combination with anti-programmed death-1/ligand-1 (PD-1/PD-L1) have been found to improve immunotherapy response in CRCLM. Machine learning-based bioinformatics may provide further understanding of the several molecular mechanisms in the liver TME that may represent potential areas for therapeutic options and precision cancer medicine. This manuscript explores the challenges associated with immunotherapy in this subset of patients, focusing on TME, immune resistance mechanisms, and potential strategies to enhance immunotherapeutic outcomes.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"7"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jia Jia Teo, Angad Chauhan, Razan Nossier, Tuan Zea Tan, Vincent Diong Weng Nga
{"title":"Novel treatment vs. standard of care in melanoma-associated leptomeningeal metastases: a systematic review and network meta-analysis.","authors":"Jia Jia Teo, Angad Chauhan, Razan Nossier, Tuan Zea Tan, Vincent Diong Weng Nga","doi":"10.21037/cco-24-104","DOIUrl":"10.21037/cco-24-104","url":null,"abstract":"<p><strong>Background: </strong>Melanoma stands out as a prevalent instigator of leptomeningeal disease (LMD) within the realm of cancer. Given the poor prognosis accompanying this condition, ongoing trials are exploring a spectrum of treatment modalities in pursuit of more effective interventions. To ascertain the most effective therapeutic strategies, we aim to compare novel treatments against the current standard of care for melanoma-associated LMD.</p><p><strong>Methods: </strong>A comprehensive search was conducted across multiple databases, including PubMed/Medline, EMBASE, Scopus, ScienceDirect and Web of Science for relevant studies published from January 2014 to September 2024. We included primary research studies, including observational studies, randomised control trials, quasi-experimental design studies, clinical trials, and experimental studies focusing on LMD caused by metastatic melanoma. Data extraction was conducted according to PRISMA guidelines and quality assessment/risk of bias was performed individually using the GRADE method. A network meta-analysis is conducted to evaluate the effects of multiple interventions within the study. Overall survival outcomes were quantified using log hazard ratio. The protocol for this study was registered on PROSPERO (CRD42024529626).</p><p><strong>Results: </strong>Out of 843 records screened for eligibility, seven carefully chosen studies, meeting our specific inclusion criteria, provided insights into the management of 397 patients grappling with LMD due to metastatic melanoma. These studies vary in design: one observational cohort study with 29 participants, a clinical trial with 25 patients, four retrospective cohort studies ranging from 39 to 190 participants and one experimental study with 24 patients. The chosen studies contain moderate to high risks of bias, with low heterogeneity (I2=13.4%). Immunotherapy with or without targeted therapy is the most effective intervention.</p><p><strong>Conclusions: </strong>Despite the escalating breakthroughs of treatment options in melanoma-associated LMD, further studies may be imperative to conclusively determine whether the newer therapeutic options yield superior outcomes compared to the current standard of care.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 1","pages":"4"},"PeriodicalIF":2.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jens Benn Sørensen, Eric Santoni-Rugiu, Edyta Maria Urbanska
{"title":"Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile.","authors":"Jens Benn Sørensen, Eric Santoni-Rugiu, Edyta Maria Urbanska","doi":"10.21037/cco-24-19","DOIUrl":"10.21037/cco-24-19","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"88"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Postoperative concurrent chemoradiotherapy plus apatinib for patients with high-grade glioma: a retrospective cohort study.","authors":"Lvjuan Cai, Jing Feng, Xiaoyan Li, Wenmin Ying, Guo Li, Huachun Luo, Xinpeng Wang, Mengjing Wu, Zhichao Fu","doi":"10.21037/cco-24-51","DOIUrl":"10.21037/cco-24-51","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy plus temozolomide followed by adjuvant temozolomide was the standard treatment for high-grade gliomas. This study aimed to explore the effectiveness and safety of the addition of apatinib in patients with high-grade gliomas after surgery.</p><p><strong>Methods: </strong>In this retrospective cohort study, patients with high-grade glioma [World Health Organization (WHO) grade III or IV] treated with apatinib and concurrent chemoradiotherapy (cCRT) after surgery from October 2017 to February 2021 were reviewed. High-grade glioma patients used cCRT alone in the same period were reviewed as the control group. Progression-free survival (PFS), overall survival (OS), the grade of peritumoral brain edema (PTBE) and safety profiles were recorded. Cox regression analyses were used to determine the associated factors of PFS and OS.</p><p><strong>Results: </strong>A total of 60 patients with high-grade glioma were reviewed, with 30 patients in the apatinib plus cCRT group and 30 patients in the cCRT group. The median PFS of the apatinib plus cCRT group compared with the cCRT group was 8.53 vs. 7.33 months (P=0.62), and the median OS was 13.70 vs. 14.30 months (P=0.93). Multivariate analysis revealed that only pathological grade was independently associated with PFS [hazard ratio (HR) =4.445, 95% confidence interval (CI): 1.857 to 10.641, P<0.001] and OS (HR =3.737, 95% CI: 1.530 to 9.123, P=0.004). The apatinib plus cCRT also improved PTBE (P=0.001), and decrease the corticosteroids use than cCRT alone (P=0.002). No grade 3 or higher adverse event was observed in both groups.</p><p><strong>Conclusions: </strong>Post-operative cCRT plus apatinib was feasible for patients with high-grade glioma, with manageable toxicities.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"13 6","pages":"82"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Artificial intelligence assistance during upper endoscopy: a game changer in detection of esophageal squamous cell carcinoma?","authors":"Annemijn D I Maan, Arjun D Koch","doi":"10.21037/cco-24-46","DOIUrl":"10.21037/cco-24-46","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"89"},"PeriodicalIF":2.1,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}